Generation and characterization of monoclonal antibodies against choline kinase α and their potential use as diagnostic tools in cancer by Gallego Ortega, David et al.
Abstract. Choline kinase · (ChoK·) is a metabolic enzyme
involved in the synthesis of phosphatidylcholine, recently
implicated in cancer onset since it is overexpressed in a
variety of human cancers such as mammary, lung, colorectal
and prostate adenocarcinomas. Furthermore, overexpression
of ChoK· in human HEK293T cells confers them oncogenic
properties with the induction of tumors after subcutaneous
injection in nude mice. ChoK· levels in tumor samples have
been analyzed using polyclonal antibodies and Western
blotting. These techniques have considerable limitations and
do not allow for a precise and efficient evaluation of the real
significance of ChoK overexpression in human carcinogenesis.
We developed a set of monoclonal antibodies with high
specificity and sensitivity against ChoK·, and characterized
their properties. We provide evidence that the newly generated
MoAbs against ChoK· have potential use in cancer diagnosis
by conventional immunohistochemistry techniques.
Introduction
Choline kinase · (ChoK·), is the first enzyme in the Kennedy
pathway for the biosynthesis of phosphatidylcholine (PC),
the major phospholipid of biological membranes. There is
strong evidence demonstrating the implication of ChoK and
its related product, phosphorylcholine (PCho), in the process
of carcinogenesis (1-4).
ChoK is up-regulated in a high percentage of human tumor-
derived cell lines as well as in different human tumoral tissues
such as breast, lung, colon and prostate (5,6). Taken together,
these tumors represent >70% of the total number of cancer
cases in developed countries. The incidence of overexpression
or increased activity of ChoK in these four types of cancer
ranges from 40% to 60% (5-7), suggesting that ChoK· may
represent an important novel tumor marker, useful for either
diagnosis, prognosis or response to treatment.
Early and reliable procedures for cancer diagnosis provides
valuable information that can improve mangement of this
disease, helping to achieve an increase in life expectancy.
Therefore, the development of reagents and appropriate
methodologies that allows the determination of ChoK over-
expression in human tumors, could represent a significant
advance in the diagnosis of cancer. Moreover, it has been
demonstrated that inhibition of ChoK· represents an effective
antitumoral strategy with a novel mechanism of action (8-13),
and that the involvement of ChoK in carcinogenesis may be
linked to an increase in its expression in tumor cells (4-7).
Thus, an available methodology that could be used for the
determination of ChoK levels in human tissue samples could
be also useful for the identification of potential candidates
for therapy using ChoK inhibitors. Monoclonal antibodies
(MoAbs) are extensively used in biomedical research and
diagnosis of many diseases including cancer, and provide
high sensitivity and specificity, both needed for such studies.
We developed a set of monoclonal antibodies against
ChoK· useful as tools in several molecular biology tech-
niques as well as in immunohistochemical studies. Finally, we
provide preliminary evidence for the potential use of these
MoAbs as diagnostic tools in cancer.
Materials and methods
Antigen preparation and purification. Human ChoK·
expression and purification was performed as described
previously as a fused GST-ChoK· (5,14,15). A standard
procedure for purification by glutation sepharose method
was followed according to the manufacturer's instructions
(Amersham Biosciences Europe, Germany). Partially purified
ChoK· was resolved in an SDS-PAGE. The gel was sliced
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off and the piece containing ChoK homogenized in PBS with
complete Freunds Adjuvant (Sigma-Aldrich, MO) (1:1;
vol:vol).
Balb/c mice immunization. Five 8-week-old mice were
inoculated intraperitoneally with 0.5 ml of the antigen homo-
genate containing 100 μg of recombinant purified ChoK·.
Two weeks later, the first boost was inoculated in the same
manner with 100 μg of recombinant purified ChoK· but in
this case mixed with Incomplete Freund Adjuvant (Sigma-
Aldrich). This process was carried out 2 more times.
Cell fusion. Mice with a positive immune response towards
ChoK· were identified by Western blotting against the partially
purified protein. Selected mice were prepared to spleenocyte
fusion 3 days after the last booster. Spleens were aseptically
removed from each mouse and poured into a dish containing
10 ml of Dulbecco's modified Eagle's medium (DMEM)
without serum, the tissue was teased until most of the cells
were released, and then the spleenocytes were collected into
a tube discarding larger pieces of tissue (16). A total of 108
spleenocytes were used for each fusion with 107 NS-1
myeloma cells. After 24-h incubation, cells were splited into
fresh medium supplemented with 10% FBS at a final
concentration of 5x105 cells/ml. For cell fusion we used 1 ml
of DMEM without serum containing 0.5 g of PEG 1500
(Roche) at 50˚C.
Selection and cloning of hybrid colonies. Successful hybrids
were selected in HAT supplemented medium as recommended
by the manufacturer (Gibco, Invitrogen, CA). Hybridoma
colonies were cloned by two consecutive rounds of the
standard minimal dilution technique.
ELISA. Multi-well microtitration plates (Nunc, Germany)
were coated using 50 μl/well of 5 μg/ml recombinant ChoK·
or GST in distilled water. After 1 h of incubation at 37˚C,
plates were washed with PBS/0.05% Tween-20, and blocked
with 10% milk in PBS overnight at 4˚C. Plates were washed
and incubated with 50 μl/well of the supernatant for 1 h at
37˚C. Wells were washed, and a goat anti-mouse HRP (horse-
radish peroxidase) secondary antibody (Dako Cytomation,
CA) added at 1:1000 dilution. Plates were incubated for 1 h at
37˚C, washed and developed using the colorimetric substrate
ABTS solution (Bio-Rad, CA). The reaction was stopped by
addition of 100 μl of SDS 0.5%.
Cytospin. A total number of 2.5x104 transfected HEK293T
cells were plated on a slide and loaded in a cytospin cuvette,
and centrifuged at 800 rpm for 3 min. An immunodetection
assay was carried out in adhered cells. After blocking non-
specific binding sites with a peroxidase blocking solution,
slides containing the adhered cells were incubated with the
supernatants from hybrid colonies for 30 min at room
temperature. After two washes with PBS a secondary anti-
mouse antibody was applied for 1 h at room temperature
and developed by standard procedures using DAB.
Cell cultures. Human embryonary kidney cells, HEK293T,
were used as a model to monitor the selection of hybrid
colonies and hybridomes and for testing the production of
anti-ChoK· antibodies. NS-1 myeloma cell line was used for
cell fusion. Mouse fibroblast NIH3T3, and NIH3T3-Tmar
that stably overexpress murine ChoK were used for testing
the cross-reactivity with murine choline kinase. Cell cultures
were maintained in 10% serum supplemented media at standard
conditions of temperature and humidity, at 5% of CO2.
Tissues and cell lysis. Tumor tissues were extracted from
surgical biopsies of patients previously diagnosed with
cancer from Hospital La Paz (Madrid, Spain). Samples were
homogenized and lysed in buffer containing 1.5 mM MgCl2,
0.2 mM EDTA, 0.3 M NaCl, 25 mM HEPES pH 7.5, 20 mM
ß-glycerophosphate and 0.1% Triton X-100 with a cocktail of
protease inhibitors.
Western blot analysis. Equal amounts of cell lysates (30 μg)
were resolved by electrophoresis in a 10% SDS-PAGE as
previously described (5). The specific binding was detected
using a chemiluminescence detection kit ECL (Amersham)
following the manufacturer's instructions.
Enzymatic activity assay. Choline kinase assays were per-
formed as described (12,14) in the presence of methyl [14C]-
choline chloride (50-60 μCi/mmol, Amersham Biosciences
Europe) at 37˚C for 30 min.
Immunoprecipitation. Hybridome culture medium was diluted
1:100 in lysis buffer and incubated with previously BSA-
blocked Protein-G coated microbeads (Sigma-Aldrich) for
1 h at 4˚C. After three washes in lysis buffer, cell lysates
were immunoprecipitated with the MoAbs linked microbeads.
To quantify the relative capability of the MoAbs produced,
we performed an in vitro ChoK activity assay in the immuno-
precipitates as described (12,14).
Immunohistochemistry. Sections of 5 μm were cut from
formalin-fixed, paraffin-embedded tissue blocks. Slides were
deparaffinated and endogenous peroxidase activity blocked
by incubation in 3% H2O2 in methanol for 10 min at room
temperature. Antigens were retrived by incubation in 940 μM
EDTA, pH 7.2, for 45 min at 155˚C. The primary anti-ChoK
monoclonal antibody was diluted at 1:2 in 1% BSA TBS.
Tissue slides were incubated for 1 h at room temperature.
Slides were rinsed in TBS and incubated with the peroxidase
based EnVision™ kit (Dako Cytomation) for 30 min at room
temperature. Specimens were then incubated with diamino-
benzidine chromogenic substrate (Dako Cytomation) for 5 min
at room temperature. Sections were counterstained with
hematoxylin. About 10 million HEK293T cells overexpresing
human ChoK· were centrifuged and paraffin embedded
following standard procedures. After 24 h of FAA fixation, cell
pellets were dehydrated starting with 50% ethanol for 30 min
and gradually increasing alcohol concentration to 100%. Pellets
were placed into xylene after embedding in liquid paraffin.
Results
Mice were inoculated with purified ChoK· and positive sera
were identified by Western blots (data not shown). Spleens
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were removed from positive mice and fused to myeloma
cells. The third week after cell fusion, 149 hybrid colonies
were screened for antibody production. Due to its simplicity
and the high number of samples that we could check at the
same time, selection of positive immunoglobulin producing
hybrid colonies was carried out by ELISA. Most of the culture
supernatants of hybrid colonies presented positive reaction
against ChoK· antigen, but only colonies that showed stronger
colour reaction than the polyclonal antibody were selected
for further analysis. Thus, 19 hybridome colonies were selected
and cloned using the minimal dilution technique. To ensure a
monoclonal culture, two consecutive rounds of subcloning in a
96-well plate was performed. A total of 49 positive clones
were obtained and further tested for antibody production.
Monoclonal antibody production screening. Selection of
positive immunoglobulin producing clones was carried out
by two consecutive methods: ELISA and cytospin immuno-
staining. ELISA was carried out to confirm the results obtained
during the cloning process. From the initial 49 clones checked
for anti-ChoK· antibody production, we selected 14 clones that
strongly recognized the antigen by ELISA (data not shown).
To further confirm these results and to ensure that anti-
bodies selected could recognize ChoK· in native conditions,
we carried out a cytospin immunostaining (data not shown).
Human embryonary kidney 293T cells (HEK293T) transiently
transfected with the ChoK· gene-encoding vector were used
for screening, using as a negative control cells transfected by
pCDNA3b empty vector. In this case, transfected cells were
adhered to a slide by centrifugation and an immunodectection
(immunostaining) assay using the hybridome culture medium
as a primary antibody was carried out. The results of the
cytospins confirmed that all the 14 hybridomes selected
produce antibodies that effectively recognize ChoK· under
native conditions. A total of 14 different clones scoring
positive for the production of anti-ChoK· immunoglobulin
by these two screening methods were selected and sub-
sequently characterized. The results of the characterization
are summarized in Table I.
Isotype determination. Determination of the class and subclass
of antibody is useful in predicting the properties of the anti-
body, and are needed for their proper use. Knowledge of
those properties facilitates choosing correctly the secondary
antibody that recognizes the MoAbs produced, or the kind of
resin that effectively binds the antibody. Furthermore, it is
also a first indication of monoclonality (17).
According to the immunization schedule, we expected a
secondary immune response in treated mice, where anti-
bodies produced are predominantly of the Immunoglobulin G
class (18). IgG antibodies often show higher affinities for the
antigen that other classes generated in primary response.
Table I shows that heavy-chains of the MoAbs generated are
Á-chains subclass 1 except AD14 that is subclass 2a, all forming
immunoglobulin-G class antibodies. Light-chains were all
κ class. Therefore anti-mouse IgG was used as a secondary
antibody for further experiments.
Western blot analysis. Immunoblots are essential to truly
establish the specificity of the antibodies for the protein of
interest (17,18). We investigated the potential use of the
MoAbs produced in WB. To that end, HEK293T cells were
transfected with the plasmid encoding for the human ChoK·
gene or with an empty vector as negative control. Equal
amounts of cell lysates were resolved in an SDS-PAGE and
transferred to a nitrocellulose membrane. Each hybridome
selected culture medium was incubated separately, and as a
positive control a polyclonal anti-serum generated against
human ChoK·, described previously, was used (1). Thirteen
out of the 14 selected media scored as positive clones. A
representative experiment is shown in Fig. 1A. No cross-
reacting or non-specific bands were observed, an indication
of their specificity.
Additionally, we tested whether the generated MoAbs
were able to recognize murine ChoK· (mChoK). Cell extracts
from NIH3T3 fibroblast stably overexpressing mChoK (Tmar-9
and Tmar-11 cells) were resolved in an SDS-PAGE as
described above. Although there is a 77% structure similarity
among human and murine choline kinase (19), only a few of
the generated MoAbs were able to effectively bind mChoK
by WB (Fig. 1B, Table I).
Immunoprecipitation. Immunoprecipitation (IP) is one of the
most widely used immunochemical techniques. In order to
characterize the ability of the generated antibodies to immuno-
precipitate ChoK·, Protein G-sepharose micro-beads were
coated with the generated MoAbs. Immunoprecipitation of
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Table I. Summary of the main features of anti-ChoK· mAbs
generated.
–––––––––––––––––––––––––––––––––––––––––––––––––
MoAb WB IP Molecular IHC Iso- Mouse 
activity type cross-
post-IP reactivity
–––––––––––––––––––––––––––––––––––––––––––––––––
AD1 ++ ++ +++ +++ IgG1.κ No
AD2 ++ ++ ++ +++ IgG1.κ No
AD3 +++ ++ - +++ IgG1.κ No
AD4 +++ ++ +++ ++ IgG1.κ No
AD5 +++ ++ +++ +++ IgG1.κ No
AD6 +++ - - + IgG1.κ Yes
AD7 +++ ++ +++ + IgG1.κ No
AD8 +++ ++ - + IgG1.κ No
AD9 +++ - - - IgG1.κ Yes
AD10 +++ - - + IgG1.κ No
AD11 +++ + - - IgG1.κ Yes
AD12 +++ - - - IgG1.κ No
AD13 +++ ++ +++ - IgG1.κ No
AD14 - ++ ++ ++ IgG2a.κ No
–––––––––––––––––––––––––––––––––––––––––––––––––
An arbitrary +/- quantification system was applied to Western blot
(WB), immunoprecipitation (IP) and immunohistochemistry  (IHC)
analysis. +++ indicates excellent, ++ good, + low, and - no
sensitivity for this technique. Enzymatic activity of ChoK in the
immunoprecipitates and murine ChoK cross-reactivity are also
indicated.
–––––––––––––––––––––––––––––––––––––––––––––––––
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Figure 1. Characterization of generated monoclonal antibodies by Western blotting. Primary AD anti-ChoK· monoclonal antibody is indicated in each case. (A)
Western blot of HEK293T cell extracts transfected with either pCDNA3 (negative control) or overexpressing ChoK·. As positive control, same extracts were
used with the polyclonal anti-ChoK· serum (left panel). A unique band corresponding to the 53 kDa ChoK· protein is recognized by several representative mono-
clonals (right panel). All monoclonals were rather specific, with no detectable non-specific band. (B) Western blot of NIH3T3 extracts (WT), and NIH3T3
overexpressing mouse ChoK· (Tmar-9 and Tmar-11).
Figure 2. Cytoimmunostaining of ChoK·. Monoclonal antibodies were scored positive if positive for staining HEK293T cells transfected by ChoK· vector.
AD2 was used for immunocitostaining of HEK293T transfected cells with the pCDNA3b empty vector (A), or ChoK· vector (B). A specific strong cytoplasmic
staining of cells transfected with ChoK is shown.
Figure 3. Identification of monoclonal antibodies to ChoK· useful for immunohistochemistry analysis. Immunohistochemistry analysis of lung (1) and breast (2)
cancer tumors with representative anti-ChoK· MoAbs. Tumor tissues appear strongly stained with low or non-labelling in the adjacent normal tissues (A). ChoK·
is not overexpressed in all tumor samples, a negative staining of each tumor type is presented (B). Counterstaining with haematoxylin.
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ChoK· was performed from transfected HEK293T cell lysates
as described above. The relative amount of ChoK· immuno-
precipitated by each antibody was determined using an in vitro
radioactive enzymatic activity assay based on the phospho-
rylation of choline to render o-phosphocholine (PCho) as
previously described (12). Samples were resolved by a thin
layer chromatography (TLC) and [14C]-PCho was quantified.
A total of 7 of the MoAb generated efficiently immuno-
precipitated ChoK and the immunoprecipitated enzyme was
fully active. However, the interaction of some of the anti-
bodies with ChoK· could interfere with its enzymatic activity
and although able to efficiently immunoprecipitate ChoK·,
scored as negative in this enzymatic assay. Thus, the ability
to immunoprecipitate ChoK· was also determined by
Western blot using the polyclonal antibody in those MoAbs
that scored negative in the enzymatic assay (data not shown).
As summarized Table I, AD3 and AD8 MoAbs, and AD11 to
a lesser extent, were able to immunoprecipitate ChoK·.
These results suggest that some of the MoAbs may interfere
with the enzymatic activity of ChoK·, resulting in a lack of
ChoK· activity in the immunoprecipitates.
Immunohistochemistry. The potential use of the generated
antibodies for immunohistochemistry (IHC) was analyzed.
Monoclonal antibodies were first tested in paraffin-
embedded cells that overexpressed ChoK· under optimal
experimental conditions. To ensure high concentrations of
the antigen, HEK293T cells were transfected with the plasmid
encoding ChoK·, and as a negative control the pCDNA3b
empty vector was used. Cell pellets of transfected HEK293T
were embedded in liquid paraffin and processed as indicated
in Materials and methods. An example of cytoimmunostaining
performed with one of the MoAb generated with a strong
and specific cytoplasmatic labelling in the HEK293T/ChoK
transfected cells is shown in Fig. 2. These results indicate
that the generated MoAbs were able to recognize ChoK· also
in paraffin-embedded cells, and therefore show a strong
affinity for ChoK·.
Since ChoK· has been recently described as a novel
oncogene (4) with high incidence in human cancer (5-7), we
tested the potential use of the generated MoAbs in cancer
diagnostic by IHC analysis in human samples. Thus, an IHC
ChoK· staining was performed in a few biopsies from patients
previously diagnosed with breast cancer (Fig. 3). The
analysis of stained biopsies reveals a strong labelling of some
of the tumor tissues, whereas a faint staining is observed in
adjacent normal tissue. However, in some biopsies both
tumor cells and normal tissues show basal ChoK staining.
Similar results were obtained when anti-ChoK· immuno-
staining was performed in biopsies of lung cancer, including
NSCLC and SCLC samples (Fig. 3). These results are in
keeping with our previous studies where 40-60% of breast,
lung, colon and prostate tumors showed increased ChoK
levels or activity. Similar results were obtained with 10
MoAbs, while 4 were negative in IHC analysis (Table I).
Discussion
Choline kinase · is a metabolic enzyme involved in the
synthesis of phospholipids. A strong implication of ChoK·
in cell proliferation, transformation and tumor progression
has been reported (4,16). Using a polyclonal antibody by
Western blot techniques, or ex vivo enzymatic analysis, over-
expression of ChoK has been implicated in human carcino-
genesis in breast, lung, colon and prostate tumors (5,6). These
biochemical discoveries suggest that ChoK· could be a
potential tumor marker in a wide variety of human cancers
(5,6). We developed a set of monoclonal antibodies against
ChoK·, and checked their usefulness in the diagnostics of
human cancer using a standard IHC assay. We demonstrate
that the MoAbs generated show high specificity and
sensitivity against the antigen. Furthermore, these mono-
clonal antibodies to ChoK· constitute a useful and reliable
tool for applications in basic research techniques such as
Western blot and immunoprecipitation, that could be
excellent tools to enrich our knowledge on ChoK· biology.
Immunoprecipitation characterization of the MoAbs revealed
the existence of different recognizing epitopes along the ChoK·
structure, some of which could interfere somehow with its
enzymatic activity. The availability of antibodies that interfere
or keep intact the ChoK· activity could be very useful for a
better understanding of its regulation. Moreover, since a
novel antitumoral strategy using specific inhibitors of ChoK·
has been demonstrated, MoAbs could be very important tools
as specific inhibitors, or essential for monitoring of ChoK
activity assays.
The results obtained in IHC assays are very encouraging
for the application of ChoK· MoAbs in cancer diagnosis,
prognosis and response to treatment. Biopsies from patients
previously diagnosed of breast or lung cancer, were probed
against immuno-ChoK· staining. In an extensive number of
cases, this technique allowed us to clearly distinguish between
tumoral tissue, where ChoK· is overexpresed and appears
strongly labelled, from surrounding normal tissues with a
faint anti-ChoK staining. Furthermore, ChoK· MoAbs were
able to identify single tumor cells embedded into normal
tissue in diffuse breast carcinomas with high reliability (data
not shown). Previous biochemical analysis of overexpression
and increased activity of ChoK· in human tumors showed
that the incidence of ChoK· ranges from 40% to 60% in
several human cancers (5-7). Thus, basal staining of tumors
where levels of ChoK· are similar to those of normal sur-
rounding cells would be expected. Indeed, several biopsies
showed no difference between normal and tumor tissues,
both scoring as negative by IHC. Therefore, the results
obtained in IHC analysis confirmed previously reported
evidence of ChoK· overexpression in human tumors.
Our results suggest that MoAbs against ChoK are useful
tools for the identification of tumor cells by IHC. This implies
a significant progress in the evaluation of ChoK overexpression
and will allow the use of these MoAbs to investigate the
relevance of ChoK overexpression in a large variety of human
tumors. The generated MoAbs could be useful for IHC
techniques in cancer diagnosis, prognosis or evaluation of
response, both in retrospective and prospective studies.
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